Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
A Phase 1 Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients With Bulky Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/28/2017
University of Miami
mi
from
Miami, FL
Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
A Phase 1 Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients With Bulky Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/28/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated:  11/28/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated: 11/28/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated:  11/28/2017
Decatur Memorial Hospital
mi
from
Decatur, IL
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated: 11/28/2017
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated:  11/28/2017
North Shore University Health System
mi
from
Evanston, IL
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated: 11/28/2017
North Shore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated:  11/28/2017
Ingalls Memorial Hospital
mi
from
Ingalls Park, IL
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated: 11/28/2017
Ingalls Memorial Hospital
mi
from
Ingalls Park, IL
Click here to add this to my saved trials
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated:  11/28/2017
Illinois Cancer Care
mi
from
Peoria, IL
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Status: Enrolling
Updated: 11/28/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers
Status: Enrolling
Updated:  11/28/2017
University of Washington School of Medicine
mi
from
Seattle, WA
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers
Status: Enrolling
Updated: 11/28/2017
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated:  12/3/2017
Hubert H. Humphrey Cancer Center
mi
from
Minneapolis, MN
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated: 12/3/2017
Hubert H. Humphrey Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/3/2017
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
mi
from
Robbinsdale, MN
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/3/2017
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/3/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/3/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Phase II Clinical Study of Weekly Topotecan in Combination With Avastin™ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Phase II Clinical Study of Weekly Topotecan in Combination With Avastin™ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Phase II Clinical Study of Weekly Topotecan in Combination With Avastin™ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy
Status: Enrolling
Updated:  12/3/2017
Park Nicollet Cancer Center
mi
from
Saint Louis Park, MN
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Phase II Clinical Study of Weekly Topotecan in Combination With Avastin™ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy
Status: Enrolling
Updated: 12/3/2017
Park Nicollet Cancer Center
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
A Pilot Trial of Platinum, Gemcitabine, or Pemetrexed Single- or Multi-Agent Therapy With Serial Tumor Specimen Collection in Patients With Advanced Non-Small-Cell Lung Cancer
Status: Enrolling
Updated:  12/5/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
A Pilot Trial of Platinum, Gemcitabine, or Pemetrexed Single- or Multi-Agent Therapy With Serial Tumor Specimen Collection in Patients With Advanced Non-Small-Cell Lung Cancer
Status: Enrolling
Updated: 12/5/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
National Jewish Health
mi
from
Denver, CO
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
University of Michigan
mi
from
Ann Arbor, MI
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Henry Ford
mi
from
Detroit, MI
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Henry Ford
mi
from
Detroit, MI
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Ohio State University
mi
from
Columbus, OH
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
University of Toledo Health Science Campus
mi
from
Toledo, OH
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
University of Toledo Health Science Campus
mi
from
Toledo, OH
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Toledo Hospital
mi
from
Toledo, OH
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Toledo Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Mercy St. Vincent Medical Center
mi
from
Toledo, OH
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Mercy St. Vincent Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Medical University of South Carolina
mi
from
Charleston, SC
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Vanderbilt
mi
from
Nashville, TN
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Tennessee Valley Veterans Admin.
mi
from
Nashville, TN
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Tennessee Valley Veterans Admin.
mi
from
Nashville, TN
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
Inova Fairfax Hospital
mi
from
Falls Church, VA
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated:  12/6/2017
The Mayo Clinic
mi
from
Rochester, MN
Validation of a Multi-gene Test for Lung Cancer Risk
Validation of a Multi-gene Test for Lung Cancer Risk
Status: Enrolling
Updated: 12/6/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
A Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Proton Therapy and Chemotherapy for Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/6/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
A Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Proton Therapy and Chemotherapy for Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/6/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Goodyear, AZ
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Anaheim, CA
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Long Beach, CA
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Farmington, CT
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Alexandria, LA
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Brewer, ME
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Brewer, ME
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Westminster, MD
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Westminster, MD
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Fairhaven, MA
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Fairhaven, MA
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Detroit, MI
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
East Setauket, NY
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
East Setauket, NY
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Durham, NC
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Hickory, NC
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Bismarck, ND
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Nashville, TN
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Research Site
mi
from
Kogarah,
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Research Site
mi
from
Kogarah,
Click here to add this to my saved trials
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/7/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/7/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials